- Home
- SIEB vs CLYM Comparison
SIEB vs CLYM Comparison
Compare SIEB & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIEB
- CLYM
- Stock Information
- Founded
- SIEB 1886
- CLYM 2018
- Country
- SIEB United States
- CLYM United States
- Employees
- SIEB N/A
- CLYM N/A
- Industry
- SIEB Investment Bankers/Brokers/Service
- CLYM
- Sector
- SIEB Finance
- CLYM
- Exchange
- SIEB Nasdaq
- CLYM NYSE
- Market Cap
- SIEB 95.1M
- CLYM 101.6M
- IPO Year
- SIEB N/A
- CLYM 2021
- Fundamental
- Price
- SIEB $2.97
- CLYM $1.20
- Analyst Decision
- SIEB
- CLYM
- Analyst Count
- SIEB 0
- CLYM 0
- Target Price
- SIEB N/A
- CLYM N/A
- AVG Volume (30 Days)
- SIEB 17.5K
- CLYM 168.2K
- Earning Date
- SIEB 05-09-2025
- CLYM 03-25-2025
- Dividend Yield
- SIEB N/A
- CLYM N/A
- EPS Growth
- SIEB 57.14
- CLYM N/A
- EPS
- SIEB 0.33
- CLYM N/A
- Revenue
- SIEB $83,639,000.00
- CLYM N/A
- Revenue This Year
- SIEB N/A
- CLYM N/A
- Revenue Next Year
- SIEB N/A
- CLYM N/A
- P/E Ratio
- SIEB $9.12
- CLYM N/A
- Revenue Growth
- SIEB 17.39
- CLYM N/A
- 52 Week Low
- SIEB $1.41
- CLYM $1.20
- 52 Week High
- SIEB $3.34
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- SIEB 67.17
- CLYM N/A
- Support Level
- SIEB $2.70
- CLYM N/A
- Resistance Level
- SIEB $3.16
- CLYM N/A
- Average True Range (ATR)
- SIEB 0.17
- CLYM 0.00
- MACD
- SIEB 0.07
- CLYM 0.00
- Stochastic Oscillator
- SIEB 77.38
- CLYM 0.00
About SIEB Siebert Financial Corp.
Siebert Financial Corp is a holding company. It conducts retail discount brokerage business through its wholly-owned subsidiary. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.